New York, November, 2022: Axiom Market Research & Consulting added a report on the global equilibrium dialysis market which includes studies on type, product type, application, and end use across various countries of key regions across the globe. The global equilibrium dialysis market was valued at USD 156.24 Million in 2022 and is projected to grow at a CAGR of 9.49 % for the forecast period of 2023 to 2029. The global market is estimated and forecasted in terms of revenue (USD Million) generated by the equilibrium dialysis market.

Increased research and developments in the drug delivery sector coupled with investments in the healthcare sector are expected to drive the market’s growth in the forecasted period. Equilibrium dialysis is among the simplest regression methods. Also, it is a very common type of procedure used for predictive analysis of continuous data. As equilibrium dialysis is a long-established statistical procedure, the properties of equilibrium dialysis statistical models are well understood and can be trained very quickly.

The report analyses the global equilibrium dialysis industry based on type, product type, application, end use, and geography. By type, the equilibrium dialysis includes key segments of linear regression, non-linear regression. On the basis of product, the market is bifurcated into instrument, and Kits and Reagents. By end-use, the market is segmented into contract research organizations, biotechnology companies, and pharmaceutical companies. The equilibrium dialysis market finds its major application in protein-drug binding assays, receptor binding assays, ligand binding assays, protein-protein interactions, protein-DNA interactions, and serum protein binding. The global equilibrium dialysis market is studied across various key countries of regions such as, North America, Europe, Asia Pacific, and the Rest of the World. 

The non-linear regression type segment is estimated to dominate the market during the forecast period.

Non-linear regression has dominated the market in the forecasted period. Fitting curves with nonlinear regression is not difficult using software programs such as Graphpad Prism. Although it is usually inappropriate to analyse transformed data, it is often helpful to display data after a linear transform. Most of the consumers find it convenient to interpret the data gathered through non-linear regression. Also, the key advantages include ease of forecasting, interpretability, and parsimony. The aforementioned pros of non-linear regression type is expected to drive the market segment in the forecasted period.

The instrument product segment is estimated to dominate the market during the forecast period.

A rapid equilibrium dialysis device has recently become commercially available offering the potential for reduced preparation and equilibration times. This instrument is used for performing equilibrium dialysis experiments in a high-throughput, automation-compatible format, and consists of disposable inserts and a base plate formatted to a standard microplate footprint. The rapid equilibrium dialysis device comprises a Teflon base plate that holds up to 48 disposable dialysis cells.  In addition, the disposable rapid equilibrium dialysis device base plates are available pre-loaded, providing convenience for scientists conducting protein-binding applications. Therefore, increased use of dialysis devices has directly accelerated the market growth of instrument segment in the forecasted period.

The protein-drug binding assays application segment is expected to dominate the equilibrium dialysis market during the forecast period

Equilibrium dialysis is one of several methods available for this purpose, and its most attractive feature continues to be its physical simplicity. 

Protien-drug binding assay is one of the most commonly used methods for assessing plasma protein binding in which non-specific binding effects are reduced compared to other methods such as ultrafiltration. Due to these key advantages, the protein-drug binding assays segment is expected to dominate the market over the projected time period. 

In 2021, Contract research organization end user accounted for the major market share

A Contract Research Organization (CRO), is an organization contracted by another company to take the lead in managing that company’s trials and complex medical testing responsibilities. These organizations reduce the cost of research and development to help businesses and institutions meet the needs of the evolving medical device and pharma industries. These organizations conduct clinical trials and provide research support services for the biotechnology, medical device, and pharmaceutical industries, as well as universities, government organizations, and foundations. Hence, with strong investments in R&D activities and a pipeline of therapeutics under development, this will lead to the growth of the contract research organization segment during the forecast period.

North America dominated equilibrium dialysis market in 2021 and is expected to witness the fastest growth in upcoming years

North America is expected to emerge as a dominant sector in the forecasted period. The key factors driving the region includes emergence of new players, presence of established players, and key strategies followed by players to capture the market better. Also, higher number of pharmaceutical companies, increasing number of hospitals, and high investments for research and development across the region is expected to drive the market in the forecasted period. 

Key Players: 

The key competitor of the market includes Harvard Apparatus (United States), Thermo Fisher (Unites States), The Nest Group, Inc. (Unites States), Aurora Borealis Control BV (Netherland), Vivaproducts (United States), Cole-Parmer (United States), Absorption Systems LLC (United States), Interchim (France), Creative Biolabs (United States), Bioduro-Sundia (China). 

Browse for More Details: https://www.axiommrc.com/product/11508-equilibrium-dialysis-market-report

Contact Us:

Ganesh Sai

United States

3 Germay Dr.Ste 4 - 4666

Wilmington DE 19804

U.S.:- + 1 (845) 875-9786

U.K.:- + 44 (0) 20 3286 9707

Email: sales@axiommrc.com